Posts by: Alice Melão, MSc

News

A single dose of an engineered antibody known as CD45-ADC can effectively eliminate disease-causing immune cells and ease the symptoms of scleroderma in mice, studies show. CD45-ADC is an ... Read more

October 28, 2019October 28, 2019

Real-World Data Show Safety, Efficacy of Opsumit for PAH Due to Scleroderma

News

Real-world clinical data support the use of Opsumit (macitentan) to treat people with pulmonary arterial hypertension (PAH) due to scleroderma (PAH-SSc). The findings revealed similar safety results and comparable ... Read more

October 4, 2019October 4, 2019

Estrogen Blocks Profibrotic Signals Driving Scleroderma, Study Suggests

News

Blocking the activity of estrogen may worsen skin fibrosis in people with scleroderma, according to a study in mice. Researchers from the Paris Descartes University, in France, believe that ... Read more

October 2, 2019October 2, 2019

Raynaud’s Association Joins October Awareness Campaign, Notes Scleroderma Link

News

Raynaud’s Association is launching several activities during October to raise awareness about Raynaud’s phenomenon, and help those affected by the condition. Either in its primary form, or linked to ... Read more

July 12, 2019July 12, 2019

First SSc Patient Dosed with Investigational Inhibitor KD025 in Phase 2 Trial

News

Kadmon Holdings started a Phase 2 clinical trial testing its inhibitor KD025, with the first patient with diffuse cutaneous systemic sclerosis (SSc) being dosed, the company announced. KD025 is a ... Read more

June 19, 2019June 19, 2019

Pirfenidone Fails to Improve Lung Function in SSc Patients with ILD, Trial Shows

News

Treatment with pirfenidone fails to improve lung function in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD), results of a clinical trial show. Trial results were discussed at ... Read more

June 17, 2019June 17, 2019

High Blood Viscosity Can Help Identify SSc Patients at Risk of PAH, Study Suggests

News

Higher blood viscosity may help clinicians identify patients with systemic sclerosis at risk of having pulmonary arterial hypertension (PAH), a serious life-threatening respiratory complication. The finding was reported by ... Read more

June 5, 2019June 5, 2019

NIH Grants $10.2M to Find New Therapies for Autoimmune Diseases, Including Scleroderma

News

Michigan Medicine researchers have been awarded approximately $10.2 million by the National Institutes of Health (NIH) Autoimmunity Centers of Excellence to explore potential treatments for autoimmune diseases, including scleroderma. Funded by ... Read more

May 16, 2019May 16, 2019

Enrollment Complete in Phase 3 Trial Testing Lenabasum in Diffuse Cutaneous SSc Patients

News

Enrollment has been completed in an ongoing Phase 3 clinical trial assessing the safety and efficacy of experimental therapy lenabasum in patients with systemic sclerosis (SSc). Corbus Pharmaceuticals, lenabasum’s ... Read more

April 26, 2019April 26, 2019

Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’

News

Corbus Pharmaceuticals is adjusting the primary efficacy outcome of the ongoing and global RESOLVE-1 Phase 3 trial of lenabasum as a possible treatment for diffuse cutaneous systemic sclerosis (SSc). The change ... Read more

Posts by: Alice Melão, MSc

Alice Melão, MSc

Antibody CD45-ADC Shows Potential to Treat Scleroderma and Other Diseases in Mice, Study Shows

Real-World Data Show Safety, Efficacy of Opsumit for PAH Due to Scleroderma

Estrogen Blocks Profibrotic Signals Driving Scleroderma, Study Suggests

Raynaud’s Association Joins October Awareness Campaign, Notes Scleroderma Link

First SSc Patient Dosed with Investigational Inhibitor KD025 in Phase 2 Trial

Pirfenidone Fails to Improve Lung Function in SSc Patients with ILD, Trial Shows

High Blood Viscosity Can Help Identify SSc Patients at Risk of PAH, Study Suggests

NIH Grants $10.2M to Find New Therapies for Autoimmune Diseases, Including Scleroderma

Enrollment Complete in Phase 3 Trial Testing Lenabasum in Diffuse Cutaneous SSc Patients

Corbus Changes Goal of Phase 3 Lenabasum Trial in Diffuse Cutaneous SSc, Sees as Step to Possible ‘Success’

Pin It on Pinterest